Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Grebely J, Feld J, Bruneau J, Daulouede J, Powis J, Bruggmann P, Matthews G, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate T, Crawford S, Dore G, Lacombe K, Dalgard O, Conway B, Cunningham E, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, D3FEAT Study Group. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy 2018; 62:94-103.
Oct 29, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Oct 29, 2018
Int J Drug Policy 2018; 62:94-103
Grebely Jason, Feld Jordan J, Bruneau Julie, Daulouede Jean-Pierre, Powis Jeff, Bruggmann Philip, Matthews Gail V, Kronborg Ian, Shaw David, Dunlop Adrian, Hellard Margaret, Applegate Tanya L, Crawford Sione, Dore Gregory J, Lacombe Karine, Dalgard Olav, Conway Brian, Cunningham Evan B, Fraser Chris, Moriggia Alberto, Gane Ed, Stedman Catherine, Cooper Curtis, Castro Erika, Schmid Patrick, Petoumenos Kathy, Hajarizadeh Behzad, Marks Phillipa, Erratt Amanda, D3FEAT Study Group
more
